Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study

This analysis of real-world data from the ongoing Myelofibrosis and Essential Thrombocythemia Observational STudy (MOST) describes the demographic and clinical characteristics, and treatment patterns of patients with clinical diagnoses of lower-risk myelofibrosis at enrollment. Future longitudinal analyses of data from the MOST study may provide insights to improve management of this understudied lower-risk patient population. This analysis of real-world data from the ongoing Myelofibrosis and Essential Thrombocythemia Observational STudy (MOST) describes the demographic and clinical characteristics, and treatment patterns of patients with clinical diagnoses of lower-risk myelofibrosis at enrollment. Future longitudinal analyses of data from the MOST study may provide insights to improve management of this understudied lower-risk patient population. Background: Clinical characteristics and treatment patterns of patients with lower-risk myelofibrosis (MF) are not well described. This analysis from the MOST (NCT02953704) assessed the demographic and clinical characteristics and treatment patterns of patients with the clinical diagnosis of lower-risk MF at enrollment. Patients and Methods: MOST is an ongoing, prospective, observational study in patients with clinical diagnoses of MF or essential thrombocythemia enrolled at clinical practices throughout the United States. Patients included in the MF cohort ( ???18 years of age) had low-risk MF by the Dynamic International Prognostic Scoring System or intermediate-1 (INT-1) risk MF (by age > 65 years only) at enrollment. Patient data were entered into an electronic case report form during usual-care visits over a planned 36 month observation period. Results: Two hundred five patients were eligible for this analysis (low risk, n = 85; INT-1 risk, n = 120; median age, 68 years [range, 35???88]); 166 patients (81.0%) had mutation testing results available. The median time from MF diagnosis to enrollment was 1.8 years. Hemoglobin and hematocrit levels were below the normal range in 50.5% and 48.7% of patients, respectively. Nearly all (98.0%) patients had comorbid conditions, most commonly hypertension (49.8%). Fatigue was the most common physician-reported MF symptom (30.7%). At enrollment, 55.6% of patients were receiving MF-directed monotherapy, most frequently hydroxyurea (46.5%) or ruxolitinib (40.4%). Conclusion: Future longitudinal analyses of data from MOST will help identify unmet needs and characterize how patients with lower-risk MF are managed throughout the disease course. (C) 2022 Elsevier Inc. All rights reserved.